Baxter International Inc. (NYSE:BAX – Get Free Report) announced a quarterly dividend on Monday, February 12th, RTT News reports. Investors of record on Friday, March 1st will be given a dividend of 0.29 per share by the medical instruments supplier on Monday, April 1st. This represents a $1.16 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend is Thursday, February 29th.
Baxter International has raised its dividend payment by an average of 6.7% annually over the last three years. Baxter International has a payout ratio of 36.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Baxter International to earn $3.23 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 35.9%.
Baxter International Stock Performance
Shares of BAX stock opened at $42.00 on Tuesday. The company’s fifty day moving average price is $39.53 and its 200-day moving average price is $37.83. The stock has a market cap of $21.33 billion, a PE ratio of 8.05, a price-to-earnings-growth ratio of 4.30 and a beta of 0.61. The company has a current ratio of 1.48, a quick ratio of 1.04 and a debt-to-equity ratio of 1.31. Baxter International has a 12 month low of $31.01 and a 12 month high of $50.21.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Laurel Wealth Advisors Inc. lifted its position in shares of Baxter International by 12.9% in the fourth quarter. Laurel Wealth Advisors Inc. now owns 8,391 shares of the medical instruments supplier’s stock valued at $428,000 after acquiring an additional 959 shares in the last quarter. KB Financial Partners LLC raised its stake in Baxter International by 6.2% during the 1st quarter. KB Financial Partners LLC now owns 4,815 shares of the medical instruments supplier’s stock valued at $373,000 after purchasing an additional 279 shares during the period. Eudaimonia Partners LLC purchased a new position in Baxter International in the 1st quarter worth approximately $340,000. Horizon Investments LLC boosted its stake in Baxter International by 10.0% in the 2nd quarter. Horizon Investments LLC now owns 6,955 shares of the medical instruments supplier’s stock worth $317,000 after purchasing an additional 633 shares during the period. Finally, Empire Financial Management Company LLC purchased a new stake in Baxter International during the 4th quarter valued at approximately $286,000. Institutional investors own 85.47% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. StockNews.com upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Friday, January 19th. UBS Group cut their price objective on shares of Baxter International from $40.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 6th. Barclays lifted their target price on shares of Baxter International from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Monday, February 12th. JPMorgan Chase & Co. raised their price target on shares of Baxter International from $38.00 to $44.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Finally, Morgan Stanley reduced their target price on Baxter International from $45.00 to $39.00 and set an “equal weight” rating for the company in a report on Monday, December 4th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $46.30.
Get Our Latest Analysis on BAX
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Further Reading
- Five stocks we like better than Baxter International
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Thinking long-term? Don’t lose interest in Pinterest
- What are earnings reports?
- Salesforce stock got a boost. Is it growing off the Nvidia boom?
- What Are the FAANG Stocks and Are They Good Investments?
- Live Nation stock rides the pent-up demand for live events
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.